A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

NCT03861052 · Completed

Last updated 2026-05-28

This study compares the effects of tirzepatide to dulaglutide in adults with type 2 diabetes to see how they impact blood sugar levels over time.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 636 people

Who can join Ages 20+ · all sexes

Timeline Started 2019-05 · est. completion 2021-03

Where 46 sites · Japan

What this study is testing ClinicalTrials.gov NCT03861052 ↗

Description as written by the study sponsor.

The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Dulaglutide also known as LY2189265 Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	tirzepatide, dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03861052 ↗